Warfarin- Clinical Use - ✔️✔️Chronic anticoagulation
Warfarin- Pregnancy - ✔️✔️CI in pregnant women--crosses placenta
Warfarin- AE - ✔️✔️Bleeding, tissue necrosis
Warfarin- Mechanism - ✔️✔️Interferes w/ vitamin K dependent clotting factors (II, VII,
IX, X, C, S)
Warfarin- Pathway, effect on PT/INR - ✔️✔️Extrinsic factor, increased PT
Digoxin- MOA - ✔️✔️Direct inhibition of Na/K ATPase --> indirect inhibition of Na/Ca
exchange
Increased Calcium concentration --> positive ionotropy.
Stimulates vagus nerve --> decrease HR
Digoxin- Clinical use - ✔️✔️Heart failure (increase contractility)
atrial fibrillation (decrease conduction at AV node and depression of SA node)
Digoxin- AE - ✔️✔️Hyperkalemia, blurry yellow vision, arrhythmias, AV block
Digoxin Toxicity- Treatment - ✔️✔️Slowly normalize K+, cardiac pacer, anti-digoxin
Fab fragments, Mg+
Beta Blockers- Mechanism - ✔️✔️Decrease SA and AV nodal activity by decreasing
cAMP/Ca2+
Decrease slope of phase 4
Beta Blockers- Use - ✔️✔️SVT, ventricular rate control for a-fib and a-flutter
Beta Blockers- AE - ✔️✔️Exacerbation of COPD/asthma
CV effects: bradycardia, AV block, HF
Metronidazole- MOA - ✔️✔️Forms toxic free radical metabolites in bacteria.
Bacteriocidal